Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurological symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via two different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurological phenotypes.
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Introduction PTEN is regarded as one of the most integral tumor suppressors due to its regulation of cellular proliferation, differentiation, and survival between multiple signaling pathways (1) . Located at 10q23, PTEN encodes a protein that functions as a dual lipid and protein phosphatase (2, 3) . Germline mutations in PTEN occur in subsets of several clinically distinct inherited disorders, such as Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome and autism spectrum disorders (4), collectively termed PTEN hamartoma tumor syndrome (PHTS). The most common PHTS is CS which is a multiple hamartoma syndrome associated with a high risk of benign and malignant tumors of the thyroid, breast, and endometrium, and megencephaly (5, 6) . Recently, our group reported that approximately 25% of individuals who meet the strict diagnostic criteria for CS, who were accrued from the community, have a germline pathogenic PTEN mutation (7) .
In a wide variety of sporadic tumors, especially glioblastoma multiforme (8) and endometrial carcinoma (9) , high frequencies of somatic PTEN mutations are well documented.
Certain mutations in DNA can result in misfolded or truncated proteins. Ubiquitindependent protein degradation is an essential mechanism of cellular clearance of such misfolded proteins. Following multiple cycles of misfolding in the endoplasmic reticulum, proteins are retro-translocated to the cytosol and conjugated with ubiquitin.
Polyubiquitinated proteins are targeted for degradation by an ATP-dependent process in proteasomes, which are located in the cytosol and nucleus (10) . Using a cohort of 3042
Cell culture. MCF-7 and HEK-293 cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS). Immortalized lymphoblast cells obtained from PHTS patients or normal controls were grown in RPMI 1640 supplemented with 20% fetal bovine serum.
Patients. We utilized peripheral blood samples and lymphoblastoid lines derived from PHTS patients with a missense mutation (C136R) and 2 common nonsense mutations (R233X and R335X) and from normal PTEN wild-type (WT) controls. Informed consent was obtained for all research participants (PHTS individuals and controls) in accordance with procedures and protocols approved by the respective Human Subjects Protection Committee of each participating institution. All research participants, whether PHTS patients or controls, participated on a voluntary (unpaid) basis.
Mutation analysis. Genomic DNA extracted from peripheral leukocytes, obtained from both PHTS patients and controls, were ampli¿ed by PCR and subjected to direct Sanger sequencing (ABI3730xl) of all PTEN exons and Àanking introns. All controls had no detectable PTEN sequence alterations.
Mutagenesis.
Each PTEN mutant was engineered using the QuikChange in vitro sitedirected mutagenesis system according to the manufacturer's instructions (Stratagene, La Jolla, CA). The accurate construction of mutant PTEN plasmids was veri¿ed by
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sequence analysis. All plasmids generated contain a FLAG-epitope at the C-terminus such that the expressed PTEN contains a C-terminal FLAG fusion.
Plasmid transfection. Cells were either grown on coverslips in 6-well plates (for confocal microscopy assays) or cultured in 60 cm 2 dishes (for Western analysis) and were transfected with plasmid DNA (PTEN-WT or PTEN-mutant) using FuGENE 6 (Roche Applied Science, Indianapolis, IN).
Protein isolation, SDS-PAGE, and Western blot analyses. For whole cell protein
lysates, cells were washed twice with ice cold PBS and harvested in M-PER buffer (Thermo Scientific, Waltham, MA) with protease inhibitors and phosphatase inhibitors.
After quantification, proteins were run on 4-15% SDS -PAGE gels and transferred to nitrocellulose. Blots were probed with primary antibodies and followed by incubation with secondary antibody and then visualized using enhanced chemiluminescence detection. FLAG M2 monoclonal antibody was purchased from Sigma Aldrich (St. Louis, MO). PTEN antibody (Clone 6H2.1) was from Cascade Biosciences (Winchester, MA).
Cyclohexmide (CHX)-chase study. MCF-7 cells stably expressing FLAG-tagged WT or mutant PTEN were incubated with CHX (50μg/mL) and were harvested at the indicated time points. Whole protein lysates were extracted and ran for Western blots using anti-FLAG antibody for transfectant PTEN and GAPDH antibody as a loading control.
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Quantitative reverse transcription-polymerase chain reaction (qRT-PCR). PTEN mRNA expression was measured by qRT-PCR to quantitate as described previously (13) using SYBR Green (Applied Biosystem, Foster City, CA). Expression of GAPDH was used as the internal control. PTEN Primers are as following: F:
AAAGGCACAAGAGGCCCTAGAT. R: CAAGTTCCGCCACTGAACATTGGAA.
Proteasome activity assay. Cells or brain tissues were homogenized in lysis buffer (0.05M HEPES, 0.005M EDTA, 0.15M NaCl, 1% Triton X-100) and 3 μg whole cell lysates (for fractionation study, 3 μg cytosolic-fraction, 10 μg nuclear-fraction), were mixed with the fluorogenic proteasome substrates Suc-LLVY-AMC (Enzo Life Sciences, Farmingdale, NY) and incubated in 37°C for 2.5 hours. Fluorescent values were read with excitation and emission wavelengths of 355 and 460 nm, respectively.
Subcellular fractionation.
For the nuclear and cytosolic fractionation, cells were harvested by trypsinization and then were incubated with buffer A (10 mM MOPS, 1.5 mM MgCl 2 , 10 mM KCl and 1% Triton X-100) for 15 min on ice with vortex for every 5 min. Cells were then centrifuged at 13,000 rpm for 5 min at 4°C and the supernatant was carefully collected as the cytosolic fraction. The pellets were then incubated with buffer A for another 15 min and separated by centrifugation at 13,000 rpm for 5 min at 4°C. The pellets were dissolved in RIPA buffer (50mM Tris-HCl, 150mM NaCl, 0.5 % NaDeoxycholate, 1% Triton X 100). Both the cytosolic and the nuclear lysates were adjusted to the same concentration before loading for the proteasome activity assay.
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Alpha-tubulin and PARP-1 were used as loading controls for cytosolic and nuclear protein fractions, separately.
Indirect immunoÀuorescence and confocal microscopy. Cells were seeded in six-well plates with cover slips. Cells were ¿xed in freshly prepared 100% methanol for 1 min at -20°C. After 5 min incubation with 0.3% Triton X-100 in PBS, the cover slips were washed three times in PBS, blocked in PBS with 10% goat serum for 30 min, incubated with primary antibodies for 1 h, washed three times in PBS and incubated with Alexa Murine model study. Pten M3M4 missense knock-in mutant mice were generated in our lab and were backcrossed more than ten times onto a CD1 genetic background. Briefly, the M3M4 double mutations were targeted into Pten exon 7 which contains the NLS-like sequence (14) . Male mouse littermates were sacrificed at 10 weeks ages; megencephalic brains were dissected out for proteasome activity assay and Western blot. Fig. 1A and B).
To determine the mechanism of protein loss, we measured PTEN mRNA levels by realtime qRT-PCR in the same samples. Only PTEN-R335X resulted in significantly diminished PTEN mRNA transcript compared to the PTEN-WT controls (at ~65% of WT1, and ~40% of WT2, respectively). The other 2 mutants, R233X and C136R, showed PTEN mRNA levels similar to those of the controls (Fig. 1C) . Our data suggest that posttranslational degradation is an important pathway for quality control of mutant PTEN protein in PHTS patients.
We then assessed proteasome activity for 12 PHTS patients with germline PTEN nonsense or missense mutations (R233X, R335X and C136R, n=4 in each group) and 10 PTEN-WT controls. We found a ~60% and a ~30% increase in the proteasome activity of lymphoblasts isolated from PHTS patients with R233X or R335X nonsense mutations, respectively (Fig. 1D) . We also found a ~30% increase in proteasome activity in the C136R mutants. We therefore conclude that at least a subset of PHTS-related PTEN cycloheximide (CHX) chase study. The WT and K125E mutant PTEN protein was stable after synthesis and was observed at 100% even after 8 hours of CHX treatment. In contrast, PTEN-C136R turned out to be highly unstable, as 50% of the mutant protein was degraded after 2 hours of CHX treatment. Moreover, MCF-7 cells expressing PTEN-K62R or PTEN-M3M4 had PTEN levels decreased by 42% and 55%, respectively, after CHX treatment for 8 hours. The data in Fig. 2A although PTEN-K62R is also an unstable PTEN mutant ( Fig. 2E and F) .
Subcellular distribution of proteasome activity in cells expressing PTEN variants.
Several mutations in PTEN have been shown to cause mislocalization (18) (19) (20) . The relatively normal proteasome activity in cells expressing the unstable PTEN-K62R mutants prompted us to investigate proteasome activity at the subcellular levels. Using confocal immunofluorescence microscopy, we were able to define subcellular localization of the PTEN mutants in MCF-7 cells. Both PTEN-K62R and PTEN-K125E are predominantly nuclear localized, whereas PTEN-M3M4, PTEN-C136R, and WT are predominantly cytosolic (Fig. 3A ).
Since nuclear proteasome activity accounts for a minimal proportion of total activity (21) proteasome activity only in the cytosol but not in the nucleus. In contrast, overexpression of PTEN-K62R led to significantly increased proteasome activity only in the nucleus but not in the cytosol (Fig. 3 B and C. Supplementary Fig. S2 ). To study the effect of nonsense mutations on PTEN protein stability and proteasome activity, we introduced the 2 most common PHTS-related PTEN nonsense mutations (R233X and R335X) into MCF-7 and HEK-293 cells. Western blot data from both cell lines showed low to no observable PTEN-R233X and R335X proteins in contrast to PTEN-WT (Fig. 5A and B, lanes 3&5) . We next asked if proteasomal degradation also plays a role in the degradation of nonsense-mutant PTEN. We compared protein levels by Western Blot after transient transfection of FLAG-tagged PTEN-WT or PTEN-R233X or -R335X) into MCF-7 and HEK293 cells, in the presence of proteasome inhibitor.
Surprisingly, there was a significantly increased amount of truncated protein following proteasome inhibitor treatment in comparison to untreated cells ( Fig. 5A and B, lanes 4&6). Thus, these two nonsense PTEN mutants may undergo some proteasome degradation, at least in vitro.
To confirm our observations in PHTS, we analyzed proteasome activity in both cell lines to determine if the instability was associated with proteasome hypersensitivity. Similar to our in vivo data, proteasome activity was inversely correlated with protein levels and was significantly elevated in comparison to the WT control ( Fig. 5C and D) . Such data further validates our hypothesis that proteasome hyperactivity is, in part, due to PTEN protein instability. (Fig. 6A, left) . Western blot reveals PTEN suppressing both PI3K/AKT and MAPK/ERK pathways (Fig. 6A, right) .
Next, we investigated the effects of the PI3K/AKT and MAPK/ERK signaling pathways on proteasome activity. We first treated MCF-7 cells with the AKT inhibitor, perifosine (24) . Although perifosine can significantly decrease P-AKT, it clearly had no obvious effect on proteasome activity (Fig. 6B) . Similarly, transfection of the active AKT1 (MyrAKT, i.e., AKT1 fused with an N-terminal myristoylation signal sequence) failed to change proteasome activity (Fig. 6C) . Surprisingly, when MCF-7 cells were treated with the MAPK/ERK inhibitor-PD98059, proteasome activity was suppressed in a dose- 
dependent manner (13% decrease at 5μM, *P<0.05; 27% decrease at 10μM, **P<0.01. Fig. 6D ). This also mimicked the effect of PTEN-WT transfection in the same cell line.
Thus, it is the protein, but not the lipid, phosphatase activity of PTEN that contributes, at least in part, to the inhibitory effect of PTEN on proteasome activity.
We further investigated the impairment of the lipid and protein phosphatase activity of PTEN by different mutations. By using P-AKT as a surrogate of the PI3K pathway, we demonstrated impaired lipid phosphatase activity in PTEN-K125E, C136R, M3M4, R233X and R335X. Similarly, by using P-ERK as a surrogate of the MAPK/ERK pathway, we found impaired protein phosphatase activity in PTEN-C136R, M3M4, R233X and R335X (Fig. 6E) . Interestingly, all the four PTEN mutants that have impaired protein phosphatase activity (C136R, M3M4, R233X and R335X) were associated with increased proteasome activity (see Fig. 1D , Fig. 2E and F) .
Discussion
In the present study, we found increased proteasome activity in lymphoblast cells from PHTS patients and in cell lines expressing germline or somatic PTEN nonsense and missense mutations. The instability of both the nonsense and missense PTEN mutants can be rescued by blocking proteasome activity through a proteasome inhibitor, MG-132, whose clinical analog, bortezomib has already been used to treat patients with multiple myeloma (25) or patients with mantle cell lymphoma (26) . In addition, our study revealed that certain PTEN missense or nonsense mutations that affect proper PTEN folding and/or protein phosphatase activity are associated with elevated proteasome activity in suggesting that it may not be a major substrate of the ubiquitin-proteasome system. To our surprise, the K62R mutant protein, which is both unstable and nuclear mislocalized, shows relatively normal proteasome activity in whole cell lysates but elevated nuclear proteasome activity when compared to the WT control cells and cells expressing other PTEN mutants. Therefore, mislocalized mutant PTEN appears to only induce proteasome activity in the compartment where it is degraded. Nuclear predominant mutant PTEN (eg K62R) induces nuclear proteasome activity whereas cytosolic predominant mutant PTEN (eg PTEN-M3M4) induces cytosolic proteasome activity.
Indeed, the nuclear ubiquitin-proteasome system is responsible for the proteasomal degradation of many short-lived nuclear proteins (29) . For instance, MyoD, which is a nuclear transcription factor that is pivotal in skeletal muscle differentiation, is degraded by the nuclear proteasome system (30) . Increased nuclear proteasome activity is associated with stress and drug resistance in solid tumors (31) . to elucidate the specific mechanism and pathogenesis of the proteasome hyperactivity induced by nuclear mislocalized mutant PTEN-K62R.
One major goal of this study was to elucidate the mechanisms of proteasome activation in PTEN mutant cells. A detailed molecular and functional analysis shows that the inhibition of MAPK activation by PD98059 led to suppressed proteasome activity, whereas no effect was observed with inhibition of the AKT activation by perifosine. (Fig. 6) . We revealed that both PTEN-WT overexpression and PD98059 treatment only suppressed proteasome activity by ~20% in MCF-7 (Fig. 6A) , whereas in the same cell line expressing unstable PTEN mutants (such as PTEN-M3M4 and PTEN-C136R, see Fig. 2E ), the latter induced more than 50% increase of proteasome activity when compared to cells expressing PTEN-WT. Therefore, it is plausible to conclude that PTEN mutants most likely cause proteasome hyperactivity via two different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity.
The proper turnover of the mutant PTEN protein by proteasomes may have essential meaning. In both human and mouse model, PTEN dose predisposes to cancer susceptibility (7, 32) . Patients with PTEN mutations that encode unstable proteins will result in PTEN dosage effects, whereas patients with PTEN mutations that encode stable proteins may result in a dominant-negative state. In addition, some mutations that abolish PTEN's phosphatase activity may still have PTEN'S tumor suppressor effects (33).
Truncated PTEN can also change the binding ability to microRNAs that affect PTEN protein levels (34). 
Proteasome hypersensitivity may be a hallmark of human cancers. Chen et al. reported that the activity of proteasomes was increased in more than 90% of primary breast cancer tissue specimens. In contrast, no activation was observed in benign solid tumors (11) .
Another study revealed increased proteasome subunit protein expression and proteasome activity in colon cancer (35) . In cancer cells, intrinsic stress response pathways are frequently activated. Accumulation of misfolded PTEN protein may lead to proteotoxic stress (36) . This can lead to progressive cellular dysfunction such as activation of prosurvival pathways and proliferation pathways (such as heat shock factors). In recent years, proteasome inhibitors have been increasingly developed and tested in human cancers. Thus, our study has some impact on clinical practice by underscoring proteasome inhibitors in the treatment of breast and other cancers with proteasomerelated PTEN instability. Indeed, two proteasome inhibitors (bortezomib and BU -32) have been tested to be effective in cultured breast cancer cells and in breast cancer xenografts (37, 38) .
In conclusion, we identified that proteasome hyperactivity and proteotoxic stress may be a common phenomenon in PHTS patients with different PTEN nonsense or missense mutations, at least in certain subsets. Our observations here may also explain why there only exists loose genotype-phenotype correlation in PHTS: seemingly disparate types and locations of mutations result in proteins with common fates, in this situation, protein instability and proteasome hyperactivity. We also found that relative proteasome hyperactivity can be affected by PTEN protein stability, protein phosphatase activity, and 
